Lindsley, who also is professor of Pharmacology,
Biochemistry and Chemistry in the medical school and College of Arts and Science, has helped pioneer development of drug - like compounds that, by adjusting the activity of receptors in the
brain, may lead to
new treatments for a wide range of
brain disorders.
Members, who have been appointed for the length of the pilot project, are: Eric Schadt, Ph.D. (Chair), chief scientific officer, Pacific Biosciences, Menlo Park, Calif.; Kevin K. Brown, M.D., professor and vice chairman, Department of Medicine, National Jewish Health, Denver; Vivian G. Cheung, M.D., professor, pediatrics and genetics, University of Pennsylvania School of Medicine and Howard Hughes Medical Institute, Philadelphia; Ross Hardison, Ph.D., professor,
biochemistry and molecular biology, The Pennsylvania State University, University Park; Allan Jones, Ph.D., chief executive officer, Allen Institute for
Brain Science, Seattle; Rebecca Pentz, Ph.D., professor of research ethics, department of hematology - oncology, Emory University School of Medicine, Atlanta; David L. Rimm, M.D., Ph.D., professor, pathology, Yale University School of Medicine,
New Haven, Conn..